Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Therapy symbols : Regn save search
Regeneron to Highlight Advances in Genetic Medicine Research at American Society of Gene and Cell Therapy (ASGCT)
Published: 2024-04-22 (Crawled : 22:00) - globenewswire.com
SNY | News | $47.69 1.15% 1.13% 1.7M
|
Health Technology
|
| O: 1.7%
H: 0.0%
C: 0.0%
REGN | News | $906.84 0.74% 0.74% 340K
|
Health Technology
|
| O: 0.51%
H: 0.78%
C: 0.18%
genetic cell research therapy
Regeneron Shares Preliminary Results Showing Gene Therapy Improves Auditory Responses in Child with Profound Genetic Hearing Loss
Published: 2023-10-26 (Crawled : 21:00) - globenewswire.com
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: -18.18%
H: 0.0%
C: 0.0%
SNY | News | $47.69 1.15% 1.13% 1.7M
|
Health Technology
|
| O: -15.73%
H: 0.0%
C: 0.0%
REGN | News | $906.84 0.74% 0.74% 340K
|
Health Technology
|
| O: 0.05%
H: 0.01%
C: -2.17%
genetic therapy results
Regeneron Completes Acquisition of Decibel Therapeutics, Adding Promising Gene Therapy Programs for Hearing Loss
Published: 2023-09-25 (Crawled : 13:00) - globenewswire.com
PPRUF | News | $364.27 37.56% 850
|
Consumer Non-Durables
|
| O: -3.71%
H: 0.0%
C: -0.92%
PPRUY | News | $36.96 -0.11% 220K
|
Manufacturing
|
| O: -4.65%
H: 0.53%
C: -0.02%
REGN | News | $906.84 0.74% 0.74% 340K
|
Health Technology
|
| O: -0.22%
H: 1.43%
C: 1.41%
acquisition therapy
Regeneron Announces Agreement with BARDA Supporting Development of Next-Generation Antibody Therapy for COVID-19 Prevention
Published: 2023-08-22 (Crawled : 18:00) - globenewswire.com
SNY | News | $47.69 1.15% 1.13% 1.7M
|
Health Technology
|
| O: -0.86%
H: 0.0%
C: 0.0%
REGN | News | $906.84 0.74% 0.74% 340K
|
Health Technology
|
| O: 0.52%
H: 0.3%
C: -0.5%
covid-19 antibody agreement therapy
Regeneron to Acquire Decibel Therapeutics, Strengthening Gene Therapy and Hearing Loss Programs
Published: 2023-08-09 (Crawled : 12:00) - globenewswire.com
PPRUF | News | $364.27 37.56% 850
|
Consumer Non-Durables
|
| O: 1.36%
H: 3.13%
C: 2.6%
PPRUY | News | $36.96 -0.11% 220K
|
Manufacturing
|
| O: 0.62%
H: 0.32%
C: -0.47%
DBTX | $4.91 -0.81% -0.2% 0
|
Health Technology
|
| O: 74.36%
H: 0.0%
C: 0.0%
REGN | News | $906.84 0.74% 0.74% 340K
|
Health Technology
|
| O: 1.9%
H: 0.0%
C: 0.0%
acquire therapy
Decibel Therapeutics Announces Approval of Clinical Trial Application by the Spanish Agency of Medicines and Medical Devices (AEMPS) to Initiate Clinical Development of Lead Gene Therapy Candidate DB-OTO
Published: 2023-05-12 (Crawled : 11:00) - globenewswire.com
DBTX | $4.91 -0.81% -0.2% 0
|
Health Technology
|
| O: 0.84%
H: 6.94%
C: 0.28%
REGN | News | $906.84 0.74% 0.74% 340K
|
Health Technology
|
| O: 0.48%
H: 0.36%
C: -0.64%
candidate approval medical application trial therapeutics therapy
Decibel Therapeutics Announces Approval of Clinical Trial Application by the U.K. Medicines and Healthcare Products Regulatory Agency for Lead Gene Therapy Candidate DB-OTO
Published: 2023-01-24 (Crawled : 13:20) - biospace.com/
DBTX | $4.91 -0.81% -0.2% 0
|
Health Technology
|
| O: -0.15%
H: 18.49%
C: 15.32%
REGN | News | $906.84 0.74% 0.74% 340K
|
Health Technology
|
| O: 0.15%
H: 0.18%
C: -0.48%
candidate application trial approval therapeutics therapy
Intellia and Regeneron Announce Initial Data from the Cardiomyopathy Arm of Ongoing Phase 1 Study of NTLA-2001, an Investigational CRISPR Therapy for the Treatment of Transthyretin (ATTR) Amyloidosis
Published: 2022-09-16 (Crawled : 12:00) - prnewswire.com
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: 0.74%
H: 0.91%
C: -0.74%
SNY | News | $47.69 1.15% 1.13% 1.7M
|
Health Technology
|
| O: -0.52%
H: 0.0%
C: 0.0%
REGN | News | $906.84 0.74% 0.74% 340K
|
Health Technology
|
| O: 0.62%
H: 1.12%
C: 0.01%
NTLA | $21.535 -1.35% -1.37% 850K
|
Health Technology
|
| O: -3.76%
H: 0.36%
C: -0.44%
ntla-2001 treatment ongoing crispr therapy study
Intellia and Regeneron Announce Updated Phase 1 Data Demonstrating a Single Dose of NTLA-2001, Investigational CRISPR Therapy for Transthyretin (ATTR) Amyloidosis, Resulted in Rapid, Deep and Sustained Reduction in Disease-Causing Protein
Published: 2022-02-28 (Crawled : 23:00) - biospace.com/
SNY | News | $47.69 1.15% 1.13% 1.7M
|
Health Technology
|
| O: -0.49%
H: 0.0%
C: 0.0%
REGN | News | $906.84 0.74% 0.74% 340K
|
Health Technology
|
| O: -1.15%
H: 1.44%
C: 1.12%
NTLA | $21.535 -1.35% -1.37% 850K
|
Health Technology
|
| O: 0.66%
H: 0.0%
C: 0.0%
ntla-2001 crispr disease intel phase 1 therapy
Intellia and Regeneron Announce Updated Phase 1 Data Demonstrating a Single Dose of NTLA-2001, an Investigational CRISPR Therapy for Transthyretin (ATTR) Amyloidosis, Resulted in Rapid, Deep and Sustained Reduction in Disease-Causing Protein
Published: 2022-02-28 (Crawled : 23:00) - biospace.com/
SNY | News | $47.69 1.15% 1.13% 1.7M
|
Health Technology
|
| O: -0.49%
H: 0.0%
C: 0.0%
REGN | News | $906.84 0.74% 0.74% 340K
|
Health Technology
|
| O: -1.15%
H: 1.44%
C: 1.12%
NTLA | $21.535 -1.35% -1.37% 850K
|
Health Technology
|
| O: 0.66%
H: 0.0%
C: 0.0%
ntla-2001 crispr disease intel phase 1 therapy
FDA Accepts for Review Libtayo® (cemiplimab-rwlc) in Combination with Chemotherapy for First-line Treatment of Advanced NSCLC
Published: 2022-01-19 (Crawled : 13:00) - biospace.com/
SNY | News | $47.69 1.15% 1.13% 1.7M
|
Health Technology
|
| O: -1.41%
H: 0.0%
C: 0.0%
REGN | News | $906.84 0.74% 0.74% 340K
|
Health Technology
|
| O: 1.84%
H: 1.79%
C: 0.18%
libtayo treatment fda therapy fda acceptance
ESMO late-breaking data show Libtayo® (cemiplimab) and chemotherapy first-line treatment combination significantly improved overall survival in patients with advanced NSCLC
Published: 2021-09-19 (Crawled : 16:20) - globenewswire.com
REGN | News | $906.84 0.74% 0.74% 340K
|
Health Technology
| Email alert
Add to watchlist
SNY | News | $47.69 1.15% 1.13% 1.7M
|
Health Technology
| Email alert
Add to watchlist
treatment therapy
Phase 3 Trial of Libtayo® (cemiplimab-rwlc) Combined with Chemotherapy Stopped Early Due to Significant Improvement in Overall Survival in Patients with First-line Advanced Non-small Cell Lung Cancer
Published: 2021-08-05 (Crawled : 11:00) - biospace.com/
SNY | News | $47.69 1.15% 1.13% 1.7M
|
Health Technology
|
| O: 1.14%
H: 0.3%
C: 0.22%
REGN | News | $906.84 0.74% 0.74% 340K
|
Health Technology
|
| O: 1.32%
H: 2.47%
C: 2.35%
lung cancer therapy cancer phase 3 trial
Phase 3 trial of Libtayo® (cemiplimab) combined with chemotherapy stopped early due to significant improvement in overall survival in patients with first-line advanced non-small cell lung cancer
Published: 2021-08-05 (Crawled : 11:00) - biospace.com/
SNY | News | $47.69 1.15% 1.13% 1.7M
|
Health Technology
|
| O: 1.14%
H: 0.3%
C: 0.22%
REGN | News | $906.84 0.74% 0.74% 340K
|
Health Technology
|
| O: 1.32%
H: 2.47%
C: 2.35%
lung cancer therapy cancer phase 3 trial
Intellia and Regeneron Announce Landmark Clinical Data Showing Deep Reduction in Disease-Causing Protein After Single Infusion of NTLA-2001, an Investigational CRISPR Therapy for Transthyretin (ATTR) Amyloidosis
Published: 2021-06-26 (Crawled : 16:20) - globenewswire.com
REGN | News | $906.84 0.74% 0.74% 340K
|
Health Technology
| Email alert
Add to watchlist
SNY | News | $47.69 1.15% 1.13% 1.7M
|
Health Technology
| Email alert
Add to watchlist
NTLA | $21.535 -1.35% -1.37% 850K
|
Health Technology
| Email alert
Add to watchlist
crispr disease therapy
Libtayo® (cemiplimab) Approved by the European Commission as the First Immunotherapy Indicated for Patients with Advanced Basal Cell Carcinoma
Published: 2021-06-25 (Crawled : 06:00) - prnewswire.com
SNY | News | $47.69 1.15% 1.13% 1.7M
|
Health Technology
|
| O: 0.55%
H: 0.68%
C: 0.57%
REGN | News | $906.84 0.74% 0.74% 340K
|
Health Technology
|
| O: -0.16%
H: 1.64%
C: 1.28%
immunotherapy europe therapy cell carcinoma
Sanofi: Libtayo® (cemiplimab) approved by the European Commission as the first immunotherapy indicated for patients with advanced basal cell carcinoma
Published: 2021-06-25 (Crawled : 06:00) - globenewswire.com
SNY | News | $47.69 1.15% 1.13% 1.7M
|
Health Technology
|
| O: 0.55%
H: 0.68%
C: 0.57%
REGN | News | $906.84 0.74% 0.74% 340K
|
Health Technology
|
| O: -0.16%
H: 1.64%
C: 1.28%
immunotherapy europe therapy cell carcinoma
FDA approves add-on therapy for patients with genetic form of severely high cholesterol
Published: 2021-04-01 (Crawled : 18:56) - fda.gov
REGN | News | $906.84 0.74% 0.74% 340K
|
Health Technology
| Email alert
Add to watchlist
therapy fda fda approval approval cholesterol
Phase 3 trial of Libtayo® (cemiplimab) monotherapy in advanced cervical cancer stopped early for positive result on overall survival
Published: 2021-03-15 (Crawled : 07:00) - globenewswire.com
SNY | News | $47.69 1.15% 1.13% 1.7M
|
Health Technology
|
| O: 0.85%
H: 0.89%
C: 0.6%
REGN | News | $906.84 0.74% 0.74% 340K
|
Health Technology
|
| O: 0.33%
H: 2.47%
C: 2.31%
positive therapy cancer phase 3 trial
Gainers vs Losers
| 78% | 22% |
Top 10 Gainers
MTTR | News 4 | $4.6 164.37% 62.17% 28M
|
AGBA | $2.94 135.2% 57.48% 66M
|
Finance
EDBL | News | $6.46 71.81% 41.8% 2M
|
MTC | $2.25 44.23% 30.67% 6M
|
Technology Services
OPRT | News | $3.175 41.11% 29.13% 12M
|
Finance
SHIM | $3.05 35.56% 26.23% 1.1M
|
HKIT | $1.345 31.86% 24.16% 390K
|
Technology Services
ABVC | $1.36 30.77% 23.53% 7.4M
|
Wholesale Trade
OST | $0.512 28.0% 21.88% 290K
|
POET | $1.59 27.2% 21.38% 4.2M
|
Manufacturing
Your saved searches
Save your searches and get alerts when important news are released.